Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment

by Andrew M. Blumenfeld
Published 2020-09-01

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

by Andrew M. Blumenfeld, Richard J. Stark, Marshall C. Freeman, Amelia Orejudos, Aubrey Manack Adams
Published 2018-02-01

Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

by Andrew M. Blumenfeld, Atul T. Patel, Ira M. Turner, Kathleen B. Mullin, Aubrey Manack Adams, John F. Rothrock
Published 2020-09-01

Lasmiditan mechanism of action – review of a selective 5-HT1F agonist

by David B. Clemow, Kirk W. Johnson, Helen M. Hochstetler, Michael H. Ossipov, Ann M. Hake, Andrew M. Blumenfeld
Published 2020-06-01

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

by William B. Young, J. Ivan Lopez, John F. Rothrock, Amelia Orejudos, Aubrey Manack Adams, Richard B. Lipton, Andrew M. Blumenfeld
Published 2019-02-01

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

by William B. Young, J. Ivan Lopez, John F. Rothrock, Amelia Orejudos, Aubrey Manack Adams, Richard B. Lipton, Andrew M. Blumenfeld
Published 2019-01-01